EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Bictegravir’s effect on persistent low-level viremia and immunological response. BELAIR study: A pilot prospective observational study

Vasilis Petrakis iD, Petros Rafailidis, Nikoleta Babaka, Gregorios Trypsianis, Panopoulou Maria, Stavroula Zisaki, Dimitrios Papazoglou, Periklis Panagopoulos iD

International Journal of STD & AIDS · 2026

DOI: 10.1177/09564624251406062 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of STD & AIDS, 2026. Verfasst von Vasilis Petrakis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, 2nd University Department of Internal Medicine, University General Hospital Alexandroupolis, Democritus University…. Hauptthemen laut MEDLINE: HIV Infections, Viremia, Heterocyclic Compounds, 4 or More Rings, HIV-1. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Real-world experience with low-level viremia (LLV) remains under reported, leading to limited knowledge about the clinical management and impact of persistent LLV on subsequent emergence of drug resistance and virologic failure (VF). The aim of this study was to assess the effect of bictegravir on the virologic outcomes in treatment-experienced people with HIV (PWHIV) with persistent LLV. Patients and Methods An observational, prospective study in which treatment-experienced PWHIV experiencing LLV were included after switch to BIC/TAF/FTC. Baseline demographic and clinical characteristics were collected from the participants’ medical records. CD4 + T-cell counts, CD4/CD8 ratios, and HIV-RNA levels were evaluated 2, 6, 12, 18, and 24 months after initiation of BIC/TAF/FTC. Statistical analysis of the data was performed using IBM Statistical Package for Social Sciences (SPSS), version 19.0 (IBM Corp., Armonk, NY, USA).

Results

A total number of 31 PWHIV, 21 males, with a mean age of 47.08 ± 7.48 years, were included. The current ART regimen before switch was based on Integrase Strand Transfer Inhibitors (INSTIs) in 30 PWH (96.8%). The mean CD4 + T-cell count after bictegravir initiation (619.45 ± 181.71, p < 0.001) was significantly elevated compared to the baseline mean CD4 + T-cell count (485.85 ± 166.92). Two months after bictegravir initiation, viral suppression was achieved at 58.1% (n = 18), and at 90.3% (n = 28) at 12 months, which was maintained at 18 and 24 months. A significant gradual elevation of CD4/CD8 ratio was also observed (0.51 ± 0.30 before switch vs 0.69 ± 0.35 at 12 months, p < 0.001).

Conclusion

The results of the present study indicate that BIC/TAF/FTC may improve the immunological response and reduce the proportion of PWHIV experiencing persistent LLV. Further studies in larger patient series are needed to determine the full beneficial role of bictegravir.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsViremiaHeterocyclic Compounds, 4 or More RingsHIV-1Anti-HIV AgentsHumansMaleProspective StudiesMiddle AgedFemalePilot ProjectsViral LoadAdultCD4 Lymphocyte CountPyridonesRNA, ViralTreatment OutcomePiperazinesCD4-CD8 RatioAmidesHeterocyclic Compounds, 3-Ring

Stichwörter der Autor:innen

AIDSCD4 cell countHIVbictegravirlow-level viremiavirologic failure

Substanzen

bictegravirHeterocyclic Compounds, 4 or More RingsPyridonesAnti-HIV AgentsRNA, ViralPiperazinesAmidesHeterocyclic Compounds, 3-Ring

Autor:innen und Institutionen

  • Department of Infectious Diseases, 2nd University Department of Internal Medicine, University General Hospital Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Evros, Greece.
  • Laboratory of Medical Statistics, Medical School of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Evros, Greece.
  • University Laboratory of Microbiology, University General Hospital Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Evros, Greece.
  • Blood Transfusion Center, University General Hospital Alexandroupolis, Alexandroupolis, Evros, Greece.

ORCID-Profile: Vasilis Petrakis, Periklis Panagopoulos

Zitieren

APA

Petrakis, V., Rafailidis, P., Babaka, N., Trypsianis, G., Maria, P., Zisaki, S., Papazoglou, D., & Panagopoulos, P. (2026). Bictegravir’s effect on persistent low-level viremia and immunological response. BELAIR study: A pilot prospective observational study. International Journal of STD & AIDS. https://doi.org/10.1177/09564624251406062

Vancouver

Petrakis V, Rafailidis P, Babaka N, Trypsianis G, Maria P, Zisaki S, et al. Bictegravir’s effect on persistent low-level viremia and immunological response. BELAIR study: A pilot prospective observational study. International Journal of STD & AIDS. 2026. doi:10.1177/09564624251406062

BibTeX
@article{Petrakis2026,
  author = {Petrakis, Vasilis and Rafailidis, Petros and Babaka, Nikoleta and Trypsianis, Gregorios and Maria, Panopoulou and Zisaki, Stavroula and Papazoglou, Dimitrios and Panagopoulos, Periklis},
  title = {Bictegravir’s effect on persistent low-level viremia and immunological response. BELAIR study: A pilot prospective observational study},
  journal = {International Journal of STD & AIDS},
  year = {2026},
  doi = {10.1177/09564624251406062}
}
Kostenlos starten →